Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Chen, Weia; 1 | Fang, Xiang-Mingb; 1 | Wang, Xuana | Sudarshan, Sanjeev Kumar Pitlac | Hu, Xiao-Yunb; * | Chen, Hong-Weib; *
Affiliations: [a] Department of Intervention Radiology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, Jiangsu Province, China | [b] Imaging Center, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, Jiangsu Province, China | [c] Department of Medical Imaging, Parexel international PVT LTD, Musheerabad, Hyderabad, Telangana, India
Correspondence: [*] Corresponding authors: Xiao-Yun HU, M.D., Ph.D, Imaging center, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, No. 299, Qingyang road, Wuxi 214023, Jiangsu Province, China. Tel.: +86 510 85350235; Fax: +86 510 85350555; Email: 54555154@qq.com and Hong-wei Chen, M.D., Imaging center,The Affiliated Wuxi People's Hospital of Nanjing Medical University, No. 299, Qingyang road, Wuxi 214023, Jiangsu Province, China. Tel.: +86 510 85350235; Fax: +86 510 85350555; E-mail: chw6312@163.com.
Note: [1] These authors are contributed equally to this work as the first co-authors.
Abstract: Purpose:To evaluate the clinical efficacy of percutaneous trans-hepatic integrated 125I seed stents implantation for malignant lower biliary tract obstruction. Methods:Thirty-two patients with malignant lower biliary obstruction were randomly divided into two groups. One group underwent the therapy with integrated 125I seed stents (Test group, n = 13), and another group received conventional metal stents implantation for treatment (Control group, n = 19). The pre- and post-operative changes in biochemical indices, white blood cell count, IgG level, stent patency, survival time, tumor size and complications were compared between the two groups. RECIST 1.1 (Response Evaluation Criteria In Solid Tumors) was used to evaluate therapeutic effects. The average follow-up time was 12.3 months. Results:The differences between pre- and post-operative (30 days) intragroup biochemical indices had statistically significant difference (P < 0.05), but there were no significant differences (P > 0.05) in leukocyte counts and IgG levels. As to the median time of stent patency and patients’ survival, there were significant differences (P < 0.05) between Control and Test groups (3.9 months vs. 8.1 months, 139 days vs. 298 days, respectively). Three months after the operation, the average tumor size was reduced in the Test group, but was increased in the Control group (P < 0.05). There was no significant difference in the incidence of complications between the two groups. The evaluation results using RECIST 1.1 showed that there were statistically significant differences between the two groups in terms of the rates of remission, control, and progression (χ2 = 17.5, P < 0.05). Conclusions:The study indicates that integrated 125I seed stents are effective in reducing jaundice symptoms, inhibiting tumor growth, improving stent patency and prolonging patient survival, which may serve as a safer and more feasible method in treating malignant lower biliary obstruction with minimal invasiveness.
Keywords: Brachytherapy, stents, biliary obstruction, cancer
DOI: 10.3233/XST-180403
Journal: Journal of X-Ray Science and Technology, vol. 26, no. 5, pp. 865-875, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl